Phase 3 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been confirmed by laboratory testing to have early-stage breast cancer or a non-invasive breast condition (such as DCIS), where the disease is small, localised, and has not spread to lymph nodes or other parts of the body.
- People whose cancer or area of concern, if found in more than one small spot, measures no more than 3.0 cm across in total.
- People whose surgeon was able to remove the cancer with a clear border of healthy tissue of at least 0.2 cm around it.
- People with certain cancer types (lobular breast cancer or high-grade DCIS) who have had an MRI scan as part of their initial assessment to confirm the disease is localised.
- People with DCIS who had an MRI scan before their lumpectomy (cancer removal surgery).
- People where any suspicious areas seen on MRI that were outside the planned surgery area have been further checked by ultrasound or biopsy to rule out disease in other areas of the breast.
- People who had cancerous calcium deposits visible on mammogram and have had a follow-up mammogram after surgery confirming those deposits were fully removed.
- People willing to complete additional screening steps as outlined in the trial's protocol.
- People who have had small marker clips (called fiducial markers) successfully placed in the breast to guide radiation treatment, and where those markers stay in position without moving.
- People where the area to be treated with radiation makes up no more than 25% of the affected breast.
- People for whom radiation treatment is planned to start within 10 weeks of their surgery.
Who may not be able to join:
- People who are pregnant or breastfeeding.
- People who have a connective tissue disorder (a condition affecting collagen in the body, such as lupus or scleroderma).
- People whose surgery did not achieve a clear enough border of healthy tissue around the cancer (less than 0.2 cm).
- People who still have suspicious or cancerous calcium deposits remaining after surgery.
- People whose cancer is found in clearly separate, distinct areas of the breast, or where microscopic disease spans more than 3.0 cm.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Charles Leonard, MD, Rocky Mountain Cancer Centers
Phone: 303-418-7607
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prevalence of breast pain after Accelerated Partial Breast Radiotherapy (APBI); Prevalence of chest wall pain after Accelerated Partial Breast Radiotherapy (APBI)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.